Akebia Therapeutics is refocusing on Vafseo for dialysis patients, discontinuing expansion to non-dialysis, which has reset ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

In the sophisticated world of endocrinology and molecular biology, few compounds have sparked as much curiosity as CJC-1295 DAC. As a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), this ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Dementia has long been framed as a slow, irreversible loss of neurons, but a new line of research is shifting attention to the blood vessels that feed the brain. Scientists are now testing whether ...

A bacterium living quietly in the intestines of a tiny tree frog has done something cancer researchers spend careers chasing: ...

That’s the Linville Falls Winery experience in a nutshell. Nestled in the picturesque Blue Ridge Mountains near Newland, North Carolina, this vineyard offers the kind of day trip that makes you ...

Tucked along the western shore of Narragansett Bay sits a place where time seems to slow down, historic buildings whisper stories of the past, and the gentle lapping of water against docks creates ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.